Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
67%(2 trials)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_1
1
20%
Ph phase_2
3
60%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
N/A1 (20.0%)

Trials by Status

completed360%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_2

Oxytocin Plus Self-compassion Training in Borderline Personality Disorder

NCT07551882
completednot_applicable

The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

NCT06605300
recruitingphase_1

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

NCT04789148
completedphase_2

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT03197662
completedphase_2

Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

NCT02629991

Clinical Trials (5)

Showing 5 of 5 trials
NCT07551882Phase 2

Oxytocin Plus Self-compassion Training in Borderline Personality Disorder

Recruiting
NCT06605300Not Applicable

The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

Completed
NCT04789148Phase 1

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

Recruiting
NCT03197662Phase 2

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

Completed
NCT02629991Phase 2

Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5